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ABSTRACT
Objective: Determining which is the most effective solution (heparin flush compared to 
0.9% saline flush) for reducing the risk of occlusions in central venous catheters (CVC) in 
adults. Method: The systematic review followed the principles proposed by the Cochrane 
Handbook; critical analysis, extraction and synthesis of data were performed by two 
independent researchers; statistical analysis was performed using the RevMan program 
5.2.8. Results: Eight randomized controlled trials and one cohort study were included 
and the results of the meta-analysis showed no difference (RR=0.68, 95% CI=0.41-1.10; 
p=0.12). Analysis by subgroups showed that there was no difference in fully deployed 
CVC (RR=1.09, CI 95%=0.53-2.22; p=0.82); Multi-Lumen CVC showed beneficial 
effects in the heparin group (RR=0.53, CI 95%=0.29-0.95; p=0.03); in Double-Lumen 
CVC for hemodialysis (RR=1.18, CI 95%=0.08-17.82; p=0.90) and Peripherally inserted 
CVC (RR=0.14, CI 95%=0.01-2.60; p=0.19) also showed no difference. Conclusion: 
Saline solution is sufficient for maintaining patency of the central venous catheter, 
preventing the risks associated with heparin administration.
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INTRODUCTION
Inclusion of a Central Venous Catheter (CVC) is of-
ten necessary when the clinical condition of the patient 
requires monitoring of some hemodynamic parameters, 
fluid therapy, administration of drugs, blood products, par-
enteral nutrition, and dialysis, among other procedures(1). 
Although on the one hand its use has enabled therapeutic 
advances, it has also led to the origin of various associated 
risks, of which infection and catheter obstruction(1-4) can be 
highlighted; factors contributing to an increase of hospital 
internalizations, morbidity and hospitalization costs(4).
For these reasons, CVC handling, maintenance and op-
timization is complicit to the predominant value of care, 
where nurses must gather a body of knowledge and skills 
to ensure proper handling of the CVC(5).
Nevertheless, despite the existence of several interna-
tional recommendations and guidelines related to this sub-
ject, doubts still persist regarding which should be used 
when we discuss the recommended solution to maintaining 
CVC patency, since there are several practices in use in the 
clinical setting (saline, heparin, sodium citrate, and other 
chemical solutions)(6).
Historically, heparin solution has been the most com-
monly used method to maintain catheter patency, dating back 
to the 1970s(1). However, this practice seems to have con-
cealed its negative effects(1,3), of which we can highlight the 
iatrogenic effects of the drug itself, such as thrombocytopenia.
Heparin is an anticoagulant that acts at the level of the 
coagulation cascade and inhibits platelet aggregation(1), 
contributing to the occurrence of thrombocytopenia and 
bleeding, even when used in small quantities in CVC op-
timization (washing/flushing)(1,7). It is administered daily in 
hospitals to approximately 12 million patients, for whom 
there are documented cases of morbidity and mortality as-
sociated with severe complications(7). Thrombocytopenia as-
sociated with the administration of heparin is developed in 
about 1-5% of the exposed population, and it is recognized 
that intravenous exposure to heparin alone is a predictive 
factor for developing thrombocytopenia(7-8).
From a macro perspective, indiscriminate use of hepa-
rin for CVC also has negative economic and social con-
sequences when compared with the use of saline solution, 
because the obstruction of CVC implies an interruption of 
therapeutic treatments and an increase in the risks associ-
ated with catheterization for the patient, which becomes 
more important in the aspect of quality healthcare(3).
We cannot help but reflect on the different focuses that 
are necessary in this practice of nursing: thrombocytopenia 
is related to the frequent use of heparin; thrombocytopenia 
risk exists even when the exposure is minimal; heparin is 
found in various concentrations and formulations, increasing 
the risk of error in dilution preparation; and several studies 
have suggested that heparin is related to medication errors(1,3).
On the other hand, some studies suggest that saline 
flush is cost-effective, adequate and also has the benefit of 
not having the adverse effects of heparin and not having 
several presentations nor preparation required at different 
concentrations(2, 9-14). In this context, some published stud-
ies have reported that most nurses use only saline solutions, 
enhancing the fact that CVC flushing practices vary widely, 
and are currently inconsistent(15).
This fact is even more significant because most existing 
guidelines for maintaining CVC are not based on evidence 
and do not identify any recommendations that promote 
flushing with only saline solution(16). When considering 
these gaps, this issue was identified as a research priority 
that could indicate significant benefits for the reduction of 
adverse events(5). In this context, it is clear that there exists 
the need to investigate the decision of using heparin or 0.9% 
sodium chloride in CVC permeability/patency; this led us 
to develop the research question: What is the most effective 
flush to reduce central venous catheter occlusion rates in adults? 
In order to set the limits of the research, the objective was 
defined as: Determining the effectiveness of heparinized flush 
solutions compared to 0.9% saline flush in the permeability of 
central venous catheters in adults.
METHOD
To carry out this systematic literature review and to re-
spond to the previously formulated research question, we 
adopted the principles proposed by the Cochrane Hand-
book(17) and the research results were reported according to 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) statement(18-19).
It is worth mentioning that prior to the start of the em-
pirical phase of the established research process, it had been 
approved by Ethics Committee of the Escola Superior de 
Saúde de Viseu (Number 35/2013). The lead author and 
co-authors established the protocol for this review which 
has not been published.
The location and selection of studies were based on a 
process consisting of three stages:
1) An initial naturalistic research limited to MEDLINE 
and CINAHL was performed, followed by an analysis 
of the words in the titles, abstracts and indexing terms 
used to describe the studies. Then we decided to confirm 
if the preliminary terms constituted MeSH descriptors 
via the website http://www.ncbi.nlm.nih.gov/mesh, 
obtaining positive response for: #1 MeSH descriptor 
“Catheterization, central venous” (explode all trees); #2 
MeSH descriptor “Catheterization” (explode all trees); 
#3 MeSH descriptor “Catheters” (explode all trees); 
#4 MeSH descriptor “Heparin” (explode all trees); #5 
MeSH descriptor “Sodium chloride” (explode all trees).
2) The second research was carried out between December 
2013 and February 2014, replicated in May 2015, and 
included electronic research in the following databases: 
CINAHL Plus with Full Text, MedicLatina, MED-
LINE with Full Text, Cochrane Database of System-
atic Reviews, Cochrane Central Register of Controlled 
Trials, Nursing & Allied Health Collection: Compre-
hensive (via EBSCO); Elsevier – Science Direct (via b-
on – Online Knowledge Library); JBI Library; Scopus; 
Scielo – Scientific Electronic Library Online; Academic 
Google (for extracting full text articles that could not be 
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obtained by other means) – through Boolean combina-
tion of all identified keywords: #6 [#1 OR #2 OR #3 
AND #4 AND #5] (subject); #7 [central venous cath-
eter* OR catheter*AND heparin OR sodium chloride] 
(title and abstract).
3) Finally, the list of references of all identified studies was 
analyzed to extract additional studies.
Inclusion criteria:
Participants: patients with central venous catheters 
(of any kind). Adults aged 18 or older in the hospital 
and/or clinical setting. Exclusion criteria included pa-
tients with coagulation disorders, hemorrhagic disease, 
family history of heparin allergy, who had prolonged 
oral or systemic treatment with anticoagulant drugs; and 
patients indicated for abdominal or orthopedic surgery.
Intervention: studies comparing the effectiveness of 
different washing solutions (flush) to maintain the per-
meability of different types of central venous catheters;
Comparisons: all heparinized solutions described in 
the literature vs. 0.9% saline solution;
Outcome: CVC occlusion rate (defined as inability to 
infuse fluid through the catheter due to an obstruction);
Design: only experimental studies were included, 
including randomized controlled trials, non-random-
ized controlled studies; and quasi-experimental studies, 
including before-and-after studies and cohort studies; 
studies published in English, Spanish and Portuguese; 
published from January 2000 to May 2015.
A critical appraisal was done prior to inclusion in the 
review by two reviewers with experience in the isolated 
method, and neither had knowledge of test results at any 
time during this process(17).
The tools for critical appraisal were: Grid for critical 
evaluation of an article describing a prospective, randomized 
and controlled clinical study of the Centro de Estudos de 
Medicina Baseada na Evidência da Faculdade de Medic-
ina de Lisboa, Portugal, which only considers high-quality 
studies which met a score equal to or higher than 75%(20) to 
assess RCT (Randomized Clinical Trial); and JBI Critical 
Appraisal Checklist for Cohort and Case-Control Studies that 
according to the consensus of the authors are considered 
quality studies that obtain up to two negative responses(21-22) 
to assess cohort studies. In the absence of consensus among 
the reviewers, disagreements that emerged were resolved 
through discussion with the inclusion of a third reviewer(22).
Data were extracted from the included studies in the 
corpus by two isolated reviewers using the instrument The 
Joanna Briggs Institute data extraction form for systematic 
review of experimental/observational studies, with disagree-
ments being resolved by discussion or a third reviewer. The 
authors were contacted for information or missing data that 
needed clarification(22).
In the process of synthesis, quantitative data were 
grouped and meta-analysis was performed with the use of 
Cochrane Collaboration’s Review Manager software (Rev-
Man 5.2.8; <http://ims.cochrane.org/RevMan>). All results 
were subjected to dual input data.
The results were expressed in relative risk (RR) with 
95% confidence intervals, as referring to dichotomous data 
(categorical data).
The Q test and I2 were calculated to verify the existence 
of heterogeneity among studies, where a I² value close to 
0% indicates no heterogeneity, close to 25% indicates low 
heterogeneity, close to 50% indicates moderate heterogene-
ity, and close to 75% indicates high heterogeneity among 
the studies(23). Due to the heterogeneity found, analyses were 
performed with the use of the random effects model(21-23), 
which implies that the effect of interest is not the same across 
all the studies, assuming the existence of a certain degree of 
clinical heterogeneity that is not liable to be controlled(23).
Levels of evidence and grades of recommendation were 
established based on the classification currently used(24).
Effectiveness comparison of heparinized flush solutions 
with 0.9% saline flush on CVC permeability was performed 
through three analyses (meta-analysis by subgroups): by 
CVC type, by design of the included studies and by their 
setting (context).
RESULTS
Of all the studies identified by the method explained in 
the previous section, we noted that the first selected sample 
comprised 4,649 studies.
Two independent researchers excluded 292 studies 
based on the inclusion criteria by reading the titles and 
1,854 by reading the abstract.
After analyzing the full text of the articles (n=36), 
28 studies were excluded, resulting in a corpus consist-
ing of eight studies. Bibliography analysis of identified 
reference articles also allowed the inclusion of another 
study, thus nine studies were considered for critical 
appraisal: eight RCT(2,6,9,11-14, 16) and one cohort study(10).
The entire process of study corpus selection can be sum-
marized by the following flow chart (shown in Figure 1).
Excluded studies (n=2,467) 
Duplicated (n=185) 
Limiters (n=2,282) 
Studies identified by researching 
databases (n=4,649) 
 
Excluded studies for not relating to 
the subject being studied (n=1,854) 
Titles and abstract analyzed 
(n=1,890) 
Full articles excluded and reason 
(n=28) 
Interventions (n=8) Outcomes (n=0)
Design (n=12) Participants (n=8) 
Full articles evaluated with 
eligibility (n=36) 
Including one article from the 
bibliography analysis of the 
evaluated articles 
Full articles excluded during critical 
appraisal (n=0) 
Complete articles included in the 
critical appraisal (n=9) 
Studies included in the study corpus 
(n=9) 
Titles analyzed (n=2,182) Excluded studies for not relating to 
the subject being studied (n=292) 
Studies included in the quantitative 
synthesis/meta-analysis (n=7) 
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Figure 1 – Representative flowchart of study corpus refinement 
stages – Viseu, Portugal, 2015.
For a detailed explanation of the evaluation of the 
methodological quality of the studies, we present Figure 2 
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based on the “Cochrane Collaboration tool for Assessing 
risk of bias”(17).
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Figure 2 – Summary of risk of bias according to the critical ap-
praisal of the reviewers – Viseu, Portugal, 2015.
Below we present a summary of the most important 
aspects of the characteristics of the studies included in the 
study corpus, which were grouped and organized into an 
“evidence table” (see Chart 1).
We also present a summary of the most important as-
pects of the main results from analyzing the selected studies 
(see Chart 2).
Summary of quantitative data - meta-analySiS
Analyzing the results of the meta-analysis and the re-
spective forest plot (as shown in Figure 3), we can infer that 
there is no statistical significance, because the combined 
result of the meta-analysis overlaps the no-effect line.
Nevertheless, we can still point out that there is a ben-
eficial effect in the group using the heparinized solutions as 
a flush because although there is no statistical significance, 
there is increased risk of non-permeable CVC in the saline 
solution group, supported by the value of meta-analytical 
result (RR=0.68, CI 95%=0.41-1.10; p=0.12). From the 
heterogeneity study we can infer that this is statistically 
significant and it is classified as low (Tau2=0.03, χ2=4.41, 
df=4, p=0.35; I2=9%).
For the subgroup of fully deployed CVC, it was 
found that there are no statistically significant differences 
Chart 1 – Study corpus characteristics of the included studies – 
Viseu, Portugal, 2015.
Study CVC specificities
Evaluation 
of catheter 
permeability
Catheters 
duration/
time
Type of 
infusion 
(medicinal 
products 
and 
solutions)
Rabe 
et al.(6)
Triple-
Lumen CVC Every 2 days 20 days
Not re-
ported
Kaneko 
et al.(9)
Double-
Lumen CVC 
with 
urokinase
After each 
hemodialysis 
session
Not 
reported
Hemodi-
alysis
continued…
…continuation
Study CVC specificities
Evaluation 
of catheter 
permeability
Catheters 
duration/
time
Type of 
infusion 
(medicinal 
products 
and 
solutions)
Pumarola 
et al.(2)
Triple-
Lumen CVC
At 24 and 72 
hours, and 
at hospital 
discharge
Until 
catheter 
occlusion 
or medical 
discharge
Not re-
ported
Bertoglio 
et al.(10)
Fully 
deployed 
CVC
Monthly 
evaluation 
or at the 
end of each 
therapeutic 
administration
Minimum 
of 12 
months
Chemo-
therapy; 
Parenteral 
nutrition
Schallom 
et al.(11)
Multiple-
Lumen CVC
Every 8 hours, 
intravenous 
without 
continuous 
infusion
22 days
Intermittent 
and non-
specific 
continuous 
infusions
Goossens 
et al.(12)
Fully 
deployed 
CVC
Before remov-
ing the needle 
from the 
CVC; before 
and after 
each therapy 
administration 
and every 8 
weeks if not 
in use
180 days
Intermittent 
and non-
specific 
continuous 
infusions; 
Blood de-
rivatives; 
Parenteral 
nutrition
Bowers 
et al. (13)
Peripher-
ally inserted 
CVC
According 
to medical 
prescription, 
at every 12 or 
24 hours
Until 
catheter 
occlusion 
or medical 
discharge
Non-
specific 
intravenous 
therapy
Heidari 
Gorji 
et al. (16)
CVC
Every 8 hours, 
intravenous 
without 
continuous 
infusion
21 days
Non-
specific 
intravenous 
therapy
Beigi 
et al. (14)
Double-
Lumen CVC
At CVC 
placement, 
at 12 and 24 
hours
1 day Hemodi-alysis
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(RR=1.09, CI 95%=0.53-2.22; p=0.82). In the subgroup of 
CVC with multiple lumens, there was a beneficial effect in 
the heparin group, which is a statistically significant result 
(RR=0.53, CI 95%=0.29-0.95; p=0.03) and without signifi-
cant heterogeneity among the studies (Tau2=0.00; χ2=0.70, 
df=1, p=0.40; I2=0%). In the subgroup of double lumen CVC 
for hemodialysis, a beneficial effect in the saline solution 
group was verified, although it did not reach statistical sig-
nificance (RR=1.18, CI 95%=0.08-17.82; p=0.90). Finally, 
in relation to the subgroup of peripherally inserted CVC, 
statistical significance was also not observed (RR=0.14, CI 
95%=0.01-2.60; p=0.19). We emphasize that the analysis of 
the differences between subgroups reveals low heterogene-
ity (χ2=3.69, df=3, p=0.30; I2=18.7%).
Chart 2 – Main results of the studies included in the study corpus – Viseu, Portugal, 2015
Author/ Year/ 
Country
Type of study/ 
Population
Interventions
Results/Outcomes Conclusions
Critical 
appraisal 
of qualityExperimental Control
Rabe et al.(6)
(Germany)
RCT/n = 99
Participants in 
intensive care
5000IU of 
Heparin/ml Flush
0.9% saline 
solution Flush
200 mg/ml 
vitamin C 
Flush
There was no difference 
between the use of 
heparin and the SS 
(p< 0.04, log-rank test).
Heparin-solutions are 
most effective when 
compared to saline 
solution in maintaining 
CVC permeability.
80%
Kaneko et al.(9) 
(Japan)
RCT/n = 48
Hospitalized 
participants
20 ml of saline 
solution Flush
20 ml of 
saline solution 
Flush +
2 ml of 1000 
IU/ml heparin
There was no difference 
between the use of 
heparin and the SS 
(p =0.8599).
Saline solution is 
sufficient in maintaining 
central catheter 
permeability for 
hemodialysis.
75%
Pumarola 
et al.(2)
(Spain)
RCT/n = 95
Participants in 
intensive care
0.9% saline 
solution Flush
100IU 
Heparin Flush
There was no difference 
between the use 
of heparin and SS 
(p =0.744).
0.9% saline is also 
effective compared to 
100 IU or 500 IU heparin 
in maintaining CVC 
permeability.
85%
Bertoglio 
et al.(10)
(Italy)
Retrospective 
cohort study/n 
= 610
Participants in the 
cancer unit
500 IU/ SS 10 ml 
Heparin Flush
10 ml of 0.9% 
saline solution 
Flush
There was no difference 
between the use of 
heparin and SS (HR -1.2; 
95% CI: 0.6-2.5; p= 0.7).
Saline solution is as 
effective as heparinized 
solution in maintaining 
patency.
7 points
Schallom 
et al.(11)
(USA)
RCT/n = 709 
lumens/n = 341
Hospitalized 
participants
10IU Heparin/ml 
Flush
10 ml of 0.9% 
saline solution 
Flush
There was no difference 
between the use of 
heparin and SS (RR = 
1.66, 95% CI = 0.86-
3.22; p =0.136).
Saline solution may be 
preferable in maintaining 
CVC patency, when 
used for a short time, 
compared to heparin.
85%
Goossens 
et al.(12)
(Belgium)
RCT/n = 802
Participants of the 
cancer unit
300IU Heparin 
/3ml Flush
10 ml of 0.9% 
saline solution 
Flush
There was no difference 
between the use of 
heparin and SS (RR = 
0.94, 95% CI = 0.67%-
1.32%).
Saline is an effective 
solution for fully 
deployed CVC flush.
85%
Bowers 
et al. (13)
RCT/n = 102 
Hospitalized 
participants
100 IU/ml (3 ml) 
Heparin Flush
10 ml of 0.9% 
saline solution 
Flush
There was no difference 
between the use of 
heparin and SS (6% rates 
of occlusion in SS group).
Saline solution is 
sufficient in maintaining 
CVC permeability of 
peripheral insertions.
80%
Heidari Gorji 
et al. (16)
(Iran)
RCT/n = 84 
Participants in 
intensive care
10 IU/ml (3 ml) 
Heparin Flush
10 ml of 0.9% 
saline solution 
Flush
There was no difference 
between the use 
of heparin and SS 
(p= 0.872).
Saline solution is 
recommended in 
maintaining CVC 
permeability.
85%
Beigi et al. (14)
(Iran)
RCT/n = 96 
Hospitalized 
participants
1000 IU/10 ml SS 
Heparin Flush
10 ml of 0.9% 
saline solution 
Flush
There was no difference 
between the use of 
heparin and SS (no CVC 
occlusions)
Saline is effective 
in maintaining CVC 
permeability for 
hemodialysis.
80%
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DISCUSSION
First, we must mention that to have adopted strict selec-
tion criteria and rigidly followed every step of conducting 
a systematic review, we consider valid, reliable and transfer-
able results. Yet we cannot help but notice that in some of 
the included studies researchers did not practice blinding, 
and yet there were some particular aspects of the allocation, 
randomization and incomplete data that were not met.
The heterogeneity found by statistical analysis is proba-
bly due to the difference between the methodological qual-
ity of the included RCT (methodological heterogeneity), 
the fact that they do not possess wholly similar interven-
tions such as different dilutions of heparin solutions, the 
different types of CVC, and also because the populations 
have different pathology (clinical heterogeneity). We also 
acknowledge that the non-permeable definition of CVC is 
different between the included studies, which may possibly 
translate some level of statistical heterogeneity(11). Never-
theless, by assuming the existence of these heterogeneities, 
by carrying out analyzes of subgroups and fulfilling all the 
recommendations, we believe that this fact does not limit 
our conclusions.
We therefore observed that heparin CVC has been con-
sidered over the years as a traditional and useful practice in 
maintaining the permeability of CVC, however this practice 
remains shrouded in some controversy. Heparin by itself 
is not a thrombolytic agent, it does not cause lysis or clot 
“fragmentation,” but prevents the progression of previously 
existing clots by inhibiting the factors related to the process 
 
Study or Subgroup
4.1.1 Fully deployed CVC
Goossens et al. 2013
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
4.1.2 Multiple-Lumen CVC
Pumarola et al. 2007
Rabe et al. 2002
Schallom et al. 2012
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.70, df = 1 (P = 0.40); I² = 0%
Test for overall effect: Z = 2.15 (P = 0.03)
4.1.3 Double-Lumen CVC
Beigi et al. 2014
Kaneko et al. 2004
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
4.1.4 Peripherally inserted CVC
Bowers et al. 2008
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.03; Chi² = 4.41, df = 4 (P = 0.35); I² = 9%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi² = 3.69, df = 3 (P = 0.30), I² = 18.7%
Events
15
15
0
3
12
15
0
1
1
0
0
31
Total
398
398
18
33
314
365
47
22
69
52
52
884
Events
14
14
0
9
25
34
0
1
1
3
3
52
Total
404
404
25
33
395
453
49
26
75
50
50
982
Weight
37.6%
37.6%
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Figure 3 - Forest plot of heparin comparison versus saline solution for CVC permeability from RCT studies for the outcome of non-
permeable CVC for subgroups of CVC types – Viseu, Portugal, 2015.
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RESUMO
Objetivo: Determinar qual é a solução (flush heparina comparado com o flush de soro fisiológico 0.9%) mais eficaz na redução do risco 
de oclusões de cateteres venosos centrais (CVC) em adultos. Método: A revisão sistemática seguiu os princípios propostos pelo Cochrane 
Handbook; a análise crítica, a extração e a síntese dos dados foram realizadas por dois investigadores, isoladamente; e a análise estatística 
efetuada com recurso ao programa RevMan 5.2.8. Resultados: Foram incluídos oito estudos randomizados controlados e um estudo de 
of clot formation, allowing lysis of the naturally occurring 
clot. Moreover, heparin has a very short lifespan (60 to 90 
min) and no data or evidence present perfect validity of the 
dilution and therapeutic components of CVC to meet the 
therapeutic effect on one hand, and on the other and even 
more critically do not produce its undesirable side effects(10).
Moreover, there is no evidence in the literature that 
the concentration of heparin alone is related to improved 
permeable CVC rates, assuming a balance between effec-
tiveness and safety of the patient(10). However, the systemic 
effects of the use of heparin and the development of hepa-
rin-induced thrombocytopenia may constitute a problem(6).
Despite the potential benefits of saline solution, the 
change in clinical practice for a normal saline solution has 
not been widely suggested in the literature for the whole 
typology of patients and CVC. A possible explanation for 
this may be attributed to the long period of time that CVC 
remains in the patient(25-27), complications associated with 
maintaining CVC(28-31), type of infusion used (medicinal, 
solutions…)(32); if the purpose of the CVC is hemodialy-
sis(9-14) and institutional procedures for locking and flushing 
can strengthen medical belief about heparin effectiveness(10), 
thus ultimately leading to exploiting the effectiveness of 
other solutions(33) (i.e. citrate).
Although most of the study’s corpus suggest the use 
of saline solution, one study(6) concluded that heparinized 
solutions are more effective when compared to saline solu-
tion for maintaining CVC patency. It is important to note 
that the flush technique has not been described in detail 
and it was performed only every 48 hours, which may have 
contributed to the differences, for example, in comparing 
this procedure to the study(11) in which the flush technique 
has been described in detail and implemented every 8 hours. 
The same authors also point out that the strength of the 
results is due to adopting protocol operations and a higher 
nurse/patient ratio, so the standardization of practices for 
conducting a flush every 8 hours, and the criteria for the 
administrative flush order according to the intravenous 
therapy (treatments) and interventions are shown as vital 
procedures.
In defense of the determined evidence, it is also note-
worthy that our meta-analysis results indicate that there is 
no statistically significant difference between the efficacies 
of flush solutions, which is supported by the value of me-
ta-analytic results (RR=0.68, CI 95%=0.41-1.10; p=0.12). 
These results clearly show that implementing the saline so-
lution flush in maintaining patency of CVC must be trans-
ferred to clinical practice.
In short, we should mention that the consensus among 
various authors and our results are consistent, allowing us to 
draw the following conclusions: the saline solution is suf-
ficient for maintaining patency of CVC when compared to 
heparinized solutions(2,9-14,16); saline solution prevents exposure 
to complications arising from the use of heparin – these being 
thrombocytopenia, bleeding(11,12,14,16)… thereby adding signifi-
cance when associated with differences in the dilutions used 
(often by the team itself ), non-uniformity of pre-established 
protocols and potential errors of medication preparation(1).
CONCLUSION
Currently, CVC obstruction is assumed as an impor-
tant concern for health professionals because it implies 
the suspension of therapies, an increase risk to the patient 
and associated costs. In this sense, strategies to reduce this 
complication are crucial, in particular the choice of solution 
being used to maintain CVC patency.
According to available evidence, the consensus among 
several authors and the results of this systematic review 
show no significant differences between the effectiveness of 
heparinized solutions and saline 0.9% in maintaining CVC 
patency in adults (RR=0.68, CI 95%=0.41-1.10; p=0.12).
Considering that there is evidence that using saline 
solution is sufficient for maintaining CVC patency, thus 
preventing the risks associated with the administration of 
heparin, we suggest the realization and implementation of a 
new guideline; with the main purpose being better resource 
management, making the technique related to the issue of 
general research for all health professionals.
Practical imPlicationS
The interventions considered in this systematic review 
are effective and can be useful in practice (Level of Evi-
dence 1.b); health care professionals can use these interven-
tions on adults (Grade A recommendation).
reSearch imPlicationS
It is necessary to properly carry out RCT designed to 
compare the clinical benefits, economic evaluations, patient 
safety and cost-effectiveness of solutions in different groups 
of patients (comorbidities), different types of CVC, CVC 
insertion reasons (intravenous therapy, parenteral nutrition, 
chemotherapy …), according to the estimated time (short 
or long term) and covering other outcomes for establishing 
causal relationships (in addition to the number of non-
permeable CVC).
RCT that validate the application of a performance 
protocol are necessary to maintain CVC permeability by 
using 0.9% saline flush and that prove the effectiveness of 
different techniques.
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coorte e os resultados da meta-análise mostram não existir diferenças (RR=0.68, IC 95%=0.41-1.10; p=0.12). A análise por subgrupos 
mostra que nos CVC totalmente implantados não se verificaram diferenças (RR=1.09, IC 95%=0.53-2.22; p=0.82); nos CVC com 
vários lúmens existiu um efeito benéfico no grupo da heparina (RR=0.53, IC 95%=0.29-0.95; p=0.03); nos CVC de duplo lúmen para 
hemodiálise (RR=1.18, IC 95%=0.08-17.82; p=0.90) e nos CVC de inserção periférica (RR=0.14, IC 95%=0.01-2.60; p=0.19) também 
não se verificaram diferenças. Conclusão: O soro fisiológico é suficiente para manter a permeabilidade dos cateteres venosos centrais, 
prevenindo os riscos associados à administração da heparina.
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RESUMEN
Objetivo: Determinar cuál es la solución (flush con heparina comparado con el de suero fisiológico al 0,9%) más eficaz en la reducción 
del riesgo de oclusiones de catéteres venosos centrales (CVC) en adultos. Método: La revisión sistemática siguió los principios 
propuestos por el Cochrane Handbook; el análisis crítico, la extracción y la síntesis de los datos fueron realizados por dos investigadores, 
aisladamente; y el análisis estadístico fue llevado a cabo con recurso al programa RevMan 5.2.8. Resultados: Se incluyeron ocho 
estudios randomizados controlados y un estudio de cohorte, y los resultados del metaanálisis muestran no existir diferencias (RR=0.68, 
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IC 95%=0.29-0.95; p=0.03); en los CVC de doble lumen para hemodiálisis (RR=1.18, IC 95%=0.08-17.82; p=0.90) y en los CVC 
de inserción periférica (RR=0.14, IC 95%=0.01-2.60; p=0.19) tampoco se verificaron diferencias. Conclusión: El suero fisiológico es 
suficiente para mantener la permeabilidad de los catéteres venosos centrales, previniendo los riesgos asociados con la administración de 
la heparina.
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